Our studies have been focused initially on trying to demonstrate that outcomes using a mismatched unrelated donor can be improved if you use post-transplant cyclophosphamide to prevent graft-versus-host disease. But that does come at a cost – PTCy is associated with side effects. There are more toxicities or side effects in the recipients, particularly the older recipients, because of the high doses of cyclophosphamide that are being used...
Our studies have been focused initially on trying to demonstrate that outcomes using a mismatched unrelated donor can be improved if you use post-transplant cyclophosphamide to prevent graft-versus-host disease. But that does come at a cost – PTCy is associated with side effects. There are more toxicities or side effects in the recipients, particularly the older recipients, because of the high doses of cyclophosphamide that are being used. There’s more infections because the PTCy can suppress the immune system. So now our studies are focused on whether we can actually reduce the dose of PTCy to lower the risk of side effects and to lower the risk of infections after transplant and yet still retain the benefit in preventing graft-versus-host disease and we’re conducting a study that’s accruing quite well right now called OPTIMIZE where we’re attempting to do that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
